通过监督和智能技术对阿尔茨海默病进行分类.
Jabli Mohamed Amine1, Moussa Mourad1,
1NOCCS Laboratory, l'Ecole National d'Ingénieurs de Sousse ENISO, Université de Sousse, Pôle technologique de Sousse, Sousse, Tunisie.
Journal of Alzheimer's disease reports
|March 4, 2025
概括
模糊逻辑与神经成像相结合,以99.1%的准确度准确识别了阿尔茨海默氏病 (AD) 阶段. 这种方法增强了早期发现AD和轻度认知障碍 (MCI).
科学领域:
- 神经成像和机器学习
- 生物医学数据分析
背景情况:
- 最近的神经成像技术的进步,包括PET和MRI,有助于阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 的诊断.
- 将成像模式与机器学习 (ML) 结合起来,可以提高神经退行性疾病的诊断准确性.
研究的目的:
- 使用治疗前的大脑成像数据开发预测模型.
- 准确地区分正常控制 (NC),MCI和AD阶段.
- 提高对阿尔茨海默病进展的诊断精度.
主要方法:
- 使用了阿尔茨海默病神经成像计划 (ADNI) 数据库.
- 处理了 3D MRI,PET Florbetaben 和 PET Flortaucipir 的图像.
- 应用机器学习技术:模糊逻辑,CNN和MLP,具有像粉样β,tau和空空间体积这样的特征.
主要成果:
- 模糊逻辑实现了99.1%的分类准确度,超过了CNN (90.67%) 和MLP (94%).
- 多模式数据集成显著提高了性能,而不是单模式方法.
- 模糊逻辑在AD阶段的分类中表现出卓越的性能.
结论:
- 将先进的ML与多式联络神经成像相结合,可以有效地分类阿尔茨海默病的各个阶段.
- 结果解决了早期AD和MCI检测中的关键差距.
- 为未来的神经退行性疾病诊断中的临床应用提供了基础.
更多相关视频
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.8K
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.4K
相关概念视频
01:26Alzheimer's Disease: Overview
418
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
418
01:22Alzheimer's Disease: Treatment
145
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
145
01:30Dementia
87
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
87
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
92
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
92